Synthetic Biologics (SYN) Reports In-Line Q3 EPS
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/6/2026
- S&P 500, Nasdaq hit record highs as Treasury yields stall, oil slips
- Oil prices fall nearly 2% as Middle East supply concerns ease
- U.S. 10-year yield climb revives dotcom-era parallels: UBS weighs in
- Goldman flags 2 key market risks if a climb in yields persists
- Shell CEO says Middle East oil flows reach 80% of prewar levels
- HubSpot to cut 7% of workforce in restructuring plan
- Paramount Skydance to close WBD deal, change ticker to SKYD
- Citi cuts investment banking analyst program to two years - Bloomberg
- Emera and Canadian Utilities agree to merge in $72B all-share deal
- Nasdaq notches record high close as investors focus on earnings
Synthetic Biologics Reports Third Quarter 2015 Financial Results and Operational Highlights
November 5, 2015 4:01 PM ESTROCKVILLE, Md., Nov. 5, 2015 /PRNewswire/ --Â Synthetic Biologics, Inc. (NYSE MKT: SYN), a clinical-stage company focused on developing therapeutics to protect the microbiome while targeting pathogen-specific diseases, reported financial results for the three and nine months ended September 30, 2015, and provided an operational update.
"Phase 2 clinical trials for our two lead gut microbiome-focused drug candidates are ongoing and demonstrate the achievement of important milestones for Synthetic... More



